The Claim
In individuals living with HIV, statin therapy is associated with a mean reduction in low-density lipoprotein cholesterol (LDL-C) of 17.3%, with only 34.4% of patients achieving the standard therapeutic target of ≥30% LDL-C reduction, indicating a significantly attenuated lipid-lowering response compared to the general population despite comparable statin dosing.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with HIV don’t respond as well to cholesterol-lowering drugs called statins as healthy people do—even when they take the same dose. Their bad cholesterol only drops by about 17%, and only about 1 in 3 reach the goal of a 30% drop.
See the scientific wording
In persons living with HIV, statin therapy results in a mean LDL-C reduction of only 17.3%, with only 34.4% achieving the expected ≥30% reduction, indicating a substantially lower response than observed in the general population despite similar statin dosing.
What the research says
1 studyThe study reports the overall mean LDL-C reduction (−17.3%) and proportion achieving ≥30% reduction (34.4%) in a large cohort of PLWH, which is markedly lower than the 30–50% reductions expected per meta-analyses of general populations, highlighting a systemic under-response.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.